The rapid rise in investment in psychedelic R&D has been propelled by the high unmet need of, an increased prevalence of, mental health disorders after the pandemic.
In this week’s Health Tech World Podcast, Hayim Raclaw, Principle at Negev Capital, discusses whether psychedelic-based medicines are the answer to the global mental health epidemic.
Listen now on Spotify or your chosen podcast platform.
